Market Analysis: 10xGenomics Surges on September 17 Driven by Lunit Partnership, Improved Performance, and Spatial Genomics Progress

1. On August 6, the company announced quarterly results as of June 30, with revenue of $151 million, exceeding the institutional expectation of $146.788 million; a loss per share of $0.14, better than the expected loss of $0.24, and it raised FY2026 sales guidance to $610 million - $630 million.
2. On September 10, the company partnered with Lunit to incorporate the Lunit SCOPE IO AI pathology platform into its tumor biomarker discovery process, integrating data from Xenium and Atera spatial platforms with H&E pathology images to analyze biomarkers related to therapeutic response and resistance.
3. On September 10, the company’s main products are single-cell and spatial biology analysis tools, with related technologies cited in more than 10 thousand research papers; its product range includes Chromium, Visium, and Xenium instruments, consumables, and supporting software, covering tumor, immunology, and neuroscience research fields.

(Disclaimer: This content is generated by AI technology based on publicly available information. It is for reference only and does not constitute investment advice.)